Concepedia

Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group

Inge M. van der Sluis, Hester de Groot‐Kruseman, D. Maroeska W. M. te Loo, Wim J. E. Tissing, Cor van den Bos, Gertjan J.L. Kaspers, Marc Bierings, Wouter J.W. Kollen, Thorsten König, Uwe Pichlmeier,

Pediatric Blood & Cancer · 2018 · 22 citations · 15 references

DOI

Abstract

The efficacy, safety, and immunogenicity of both asparaginase preparations are comparable. This trial was registered at www.clinicaltrials.gov as #NCT00784017; EudraCT number 2006-003180-31.

References

15

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

Rob Pieters, Hester de Groot‐Kruseman, Vincent van der Velden et al. · Journal of Clinical Oncology · 2016 · 365 citations · Full text

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

Inge M. van der Sluis, Lynda M. Vrooman, Rob Pieters et al. · Haematologica · 2016 · 225 citations · Full text

, , +7

L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.

Riccardo Riccardi, John S. Holcenberg, Daniel Glaubiger et al. · PubMed · 1981 · 168 citations

, , +12

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

E. Ahlke, ULRIKE NOWAK‐GO ̈TTL, P. Schulze-Westhoff et al. · British Journal of Haematology · 1997 · 116 citations · Full text

L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure

Carmelo Rizzari, Massimo Zucchetti, Valentino Conter et al. · Annals of Oncology · 2000 · 110 citations · Full text

, , +4